Palladio Biosciences, Inc.

Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA, July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D., to the Company's Board of Directors, effective June 30, 2024. Additionally, Regina Hodits and Björn Odlander have informed the Board of their intention to step down as members effective June 30, 2024, due to other professional commitments. "We are pleased to welcome David and Marella to the Carisma Board of Directors. Their vast experience in the life sciences sector will be instrumental in advancing our cell therapy platform focused on engineered macrophages," said Sanford Zweifach, Chair of the Carisma Board of Directors. "We would also like to thank Regina and Björn for their invaluable contributions, guidance, and leadership throughout their tenure. We wish them the utmost success in their future endeavors." "Dr. Scadden's renowned expertise as a physician and medical researcher will be incredibly valuable to Carisma, and we are honored to welcome him to our Board of Directors. Ms. Thorell's experience as a public company executive and Board Member of biotech companies will enhance the business capabilities of our Board," said Steven Kelly, President and Chief Executive Officer of Carisma. "These new appointments enrich our Board's diversity of experience and perspective, providing exemplary leadership as we work with urgency to bring groundbreaking immunotherapies to patients." About David Scadden Dr. Scadden is the Gerald and Darlene Jordan Professor of Medicine and Professor of Stem Cell and Regenerative Biology at Harvard University. Dr. Scadden founded and directs the Center for Regenerative Medicine at Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute. Dr. Scadden is Chairman Emeritus and Professor of the Harvard University Department of Stem Cell and Regenerative Biology. Dr. Scadden has received numerous honors and awards and has served on the board of scientific counselors for the National Cancer Institute, the board of external experts for the National Heart, Lung, and Blood Institute, the board of directors of the International Society for Stem Cell Research and is an affiliate member of the Broad Institute of Harvard and MIT. He serves on multiple editorial boards, scientific advisory boards, and corporate boards. He is a scientific founder of Fate Therapeutics, Inc., and Dianthus Therapeutics, Inc., and also serves on the Board of Directors of Agios Pharmaceuticals, Inc., and Editas Medicine, Inc. Dr. Scadden received a bachelor's degree in English from Bucknell University and an M.D. from Case Western Reserve School of Medicine. About Marella Thorell Marella Thorell brings more than 25 years of extensive experience in finance and operations across both public and private biotech companies. Ms. Thorell is currently the Chief Financial Officer of Seres Therapeutics. Previously, she served as the Chief Financial Officer of Evelo Biosciences. Her prior roles include Chief Accounting Officer at Centessa Pharmaceuticals, Chief Financial Officer of Palladio Biosciences prior to its acquisition by Centessa, and Chief Financial Officer and Chief Operating Officer of Realm Therapeutics. Before her time at Realm Therapeutics, Ms. Thorell held positions of increasing responsibility at Campbell Soup Company and Ernst & Young, LLP. Ms. Thorell is a Director and Chair of the Audit Committee of ESSA Pharmaceuticals and was previously Chair of the Board of Vallon Pharmaceuticals before its merger in 2023. Ms. Thorell received a bachelor's degree in business from Lehigh University. About Carisma Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit . Investors: Shveta Dighe Head of Investor Relations [email protected] Media Contact: Julia Stern (763) 350-5223 [email protected] SOURCE Carisma Therapeutics Inc.

Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA, July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D., to the Company's Board of Directors, effective June 30, 2024. Additionally, Regina Hodits and Björn Odlander have informed the Board of their intention to step down as members effective June 30, 2024, due to other professional commitments. "We are pleased to welcome David and Marella to the Carisma Board of Directors. Their vast experience in the life sciences sector will be instrumental in advancing our cell therapy platform focused on engineered macrophages," said Sanford Zweifach, Chair of the Carisma Board of Directors. "We would also like to thank Regina and Björn for their invaluable contributions, guidance, and leadership throughout their tenure. We wish them the utmost success in their future endeavors." "Dr. Scadden's renowned expertise as a physician and medical researcher will be incredibly valuable to Carisma, and we are honored to welcome him to our Board of Directors. Ms. Thorell's experience as a public company executive and Board Member of biotech companies will enhance the business capabilities of our Board," said Steven Kelly, President and Chief Executive Officer of Carisma. "These new appointments enrich our Board's diversity of experience and perspective, providing exemplary leadership as we work with urgency to bring groundbreaking immunotherapies to patients." About David Scadden Dr. Scadden is the Gerald and Darlene Jordan Professor of Medicine and Professor of Stem Cell and Regenerative Biology at Harvard University. Dr. Scadden founded and directs the Center for Regenerative Medicine at Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute. Dr. Scadden is Chairman Emeritus and Professor of the Harvard University Department of Stem Cell and Regenerative Biology. Dr. Scadden has received numerous honors and awards and has served on the board of scientific counselors for the National Cancer Institute, the board of external experts for the National Heart, Lung, and Blood Institute, the board of directors of the International Society for Stem Cell Research and is an affiliate member of the Broad Institute of Harvard and MIT. He serves on multiple editorial boards, scientific advisory boards, and corporate boards. He is a scientific founder of Fate Therapeutics, Inc., and Dianthus Therapeutics, Inc., and also serves on the Board of Directors of Agios Pharmaceuticals, Inc., and Editas Medicine, Inc. Dr. Scadden received a bachelor's degree in English from Bucknell University and an M.D. from Case Western Reserve School of Medicine. About Marella Thorell Marella Thorell brings more than 25 years of extensive experience in finance and operations across both public and private biotech companies. Ms. Thorell is currently the Chief Financial Officer of Seres Therapeutics. Previously, she served as the Chief Financial Officer of Evelo Biosciences. Her prior roles include Chief Accounting Officer at Centessa Pharmaceuticals, Chief Financial Officer of Palladio Biosciences prior to its acquisition by Centessa, and Chief Financial Officer and Chief Operating Officer of Realm Therapeutics. Before her time at Realm Therapeutics, Ms. Thorell held positions of increasing responsibility at Campbell Soup Company and Ernst & Young, LLP. Ms. Thorell is a Director and Chair of the Audit Committee of ESSA Pharmaceuticals and was previously Chair of the Board of Vallon Pharmaceuticals before its merger in 2023. Ms. Thorell received a bachelor's degree in business from Lehigh University. About Carisma Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit . Investors: Shveta Dighe Head of Investor Relations investors@carismatx.com Company Codes: NASDAQ-NMS:CARM

CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“ADPKD”), is pleased to announce that Dr. Ronald Perrone has joined the Company’s Clinical Advisory Board. Dr. Allen Davidoff stated, “We are excited that Dr. Ron Perrone has agreed to join XORTX’s Clinical Advisory Board. Dr. Perrone brings substantial medical and professional experience as a thought leader, combined with clinical experience treating patients with ADPKD and kidney disease. We are privileged to have Dr. Perrone join our esteemed Clinical Advisory Board alongside current members, Dr. Petter Bjornstad, Dr. Richard Johnson, Dr. Federico Maese, Dr. Anjay Rostogi and Dr. Charles Edelstein. We look forward to the valuable contributions that he can bring to our advanced clinical program and specifically the XRX-OXY-201 registration trial designed to slow progression of ADPKD.” Dr. Ronald Perrone, MD is Professor of Medicine at Tufts University School of Medicine in Boston, Massachusetts. Dr. Perrone is board certified in Nephrology. He did his Internal Medicine residency at Grady Memorial Hospital in Atlanta and Nephrology fellowship at Boston University Medical Center. Ron’s research involves clinical investigations focused on kidney disease with a special emphasis on polycystic kidney disease (“PKD”). He is heavily involved in clinical research in ADPKD clinical trials and works with regulatory agencies such as the US Food and Drug Administration (“FDA”) to contribute to the development of database assessment tools to validate total kidney volume as a biomarker for PKD progression. Dr. Perrone’s focus on translational clinical trial interventions in ADPKD includes trials for Sanofi, Reata, Palladio Biosciences, HALT-PKD, the TAME PKD Metformin trial, TEMPO and REPRISE trials for Tolvaptan. Ron also initiated a PKD Database Consortium in 2007 which led to the creation of the PKD Outcomes Consortium in 2009. The PKD Outcomes Consortium, comprising contributors from academia, the pharmaceutical industry, National Institute of Health (“NIH”), FDA, the Clinical Data Interchange Standards Consortium (“CDISC”), and the Critical Path Institute (C-Path), is creating the groundwork for validation of for biomarkers and clinical trial and regulatory endpoints in ADPKD. This work is ongoing and involves frequent interactions with the FDA and the European Medicines Agency. A full list of Dr. Perrone’s publications can be found at: https://pubmed.ncbi.nlm.nih.gov/?term=perrone+rd. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com. For more information, please contact: Allen Davidoff, CEO Nick Rigopulos, Director of Communicationsadavidoff@xortx.com or +1 403 455 7727 nick@alpineequityadv.com or +1 617 901 0785 Kim Golodetz, LHA Investor Relations kgolodetz@lhai.com or 1 212 838 3777 Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Forward Looking Statements This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.